Motilal Oswal's research report on PI Industries
PI’s FY21 Annual Report highlights its intention to build multiple growth engines and take PI to the next level in the global arena, with more substantive participation in the Life Sciences domain. Here are the key insights: Pace of commercialization of new molecules increased Custom Synthesis and Manufacturing (CSM) saw strong growth of 35% YoY (to INR33.2b) in FY21, driven by volume growth in existing products and the commercialization of five molecules (~90% of CSM revenues come from patented molecules). FY21 saw strong growth despite 31% growth in the previous year. The order book position for the year stood at ~USD1.5b. PI operationalized two manufacturing facilities (with capacity enhancements of ~15% in key products) and commissioned a pharma lab in Rajasthan in FY21. PI also undertook process improvements for nine projects to identify and implement cost improvement opportunities at the plant level. PI received over 40 active inquiries at different stages and initiated seven new customer relationships in FY21.
Outlook
We value the stock at 40x Sep'23 EPS to arrive at TP of INR3,720. Maintain Buy.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.